Reading the tape
NASDAQ: ARVN
Arvinas, Inc.
Healthcare · Biotechnology
Market Cap
$689.50M
52w High
$14.51
52w Low
$5.90
P/E
-8.66
Volume
1.42M
Outstanding Shares
63.96M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 41.28%Revenue (TTM): -0.3%FCF (TTM): -5.59%P/S: 12th pct
What changed
The stock rose 41.28% over the last year. Revenue declined 0.3% over the trailing twelve months. Operating margin moved from -95.03% to -44.02%. Free cash flow declined 5.59% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -44.02%. A decisive move in revenue — currently down 0.3% — would be the clearest signal to resolve the ambiguity.
Company profile
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
CEORandy Teel
SectorHealthcare
IndustryBiotechnology
Employees430
IPO dateSep 27, 2018
Valuation
Forward P/E—
EV/EBITDA-8.44
Enterprise value$635.31M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth-83.95%
Gross margin99.54%▼1.98%vs FY2024
Operating margin-44.02%▲53.94%vs FY2024
ROE-18.62%▲47.41%vs FY2024
Analyst consensus
RatingBuy
Target price$13.00▲20.59%
20
Buy
5
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.94 · Revenue est $16.61M
View